Stopping trazodone abruptly can trigger a recognizable set of withdrawal symptoms, though the risk is generally considered lower than with many other antidepressants. The most common complaint is a sharp return of insomnia, often worse than what prompted the prescription in the first place. Other symptoms range from anxiety and irritability to nausea, dizziness, and headaches. Tapering gradually rather than stopping cold turkey is the standard way to minimize these effects, but how quickly you can taper depends on how long you have been taking the drug, at what dose, and how your body responds along the way.
What Trazodone Withdrawal Feels Like
People who stop trazodone suddenly tend to describe two overlapping categories of problems. The first is psychological: anxiety that can spike sharply, depressed mood that may feel worse than before treatment, irritability, agitation, and difficulty concentrating. The second is physical: headaches, nausea, dizziness, muscle aches, sweating, and a general feeling of being unwell that some people compare to the early stages of the flu. A subset of people also report “brain zaps,” brief electrical-sensation feelings in the head that are more commonly associated with SSRI withdrawal but can occur with trazodone as well.
Not everyone who stops trazodone will experience withdrawal. People who have taken it for a short period at a low dose, particularly the 25 to 50 mg range commonly prescribed off-label for sleep, may notice little more than a night or two of disrupted sleep. The risk and severity tend to increase with higher doses, longer treatment duration, and faster discontinuation. Someone who has been on 300 mg daily for years and stops overnight is far more likely to have a rough time than someone tapering off 50 mg after a few months.
Why Stopping Triggers Symptoms
Trazodone works on several receptor systems at once, which is part of what makes it versatile and also part of why stopping it can be disorienting for the body. At therapeutic antidepressant doses, it blocks the reuptake of serotonin while also antagonizing certain serotonin receptor subtypes. At the lower doses used for sleep, its sedating effects come mainly from blocking histamine receptors and alpha-adrenergic receptors. When you remove the drug, those receptor systems do not instantly recalibrate. The brain has adapted to the drug’s presence and needs time to readjust.
The histamine-blocking action is particularly relevant to the insomnia rebound that many people experience. While the drug is on board, histamine signaling is suppressed, contributing to drowsiness. When the drug is removed, histamine activity can temporarily overshoot its normal baseline, leaving you more alert and wakeful than you were before you ever started trazodone. This overshoot is a classic rebound phenomenon, distinct from true withdrawal in the strictest pharmacological sense, but it feels the same from the patient’s perspective and resolves the same way: gradually, as the brain recalibrates.
Trazodone also has a relatively short half-life of roughly five to nine hours, meaning it clears the body quickly. Drugs with short half-lives tend to produce more noticeable discontinuation effects because levels drop fast between doses. This is one reason why even people on modest doses sometimes notice something when they skip a night.
How Trazodone Compares to Other Antidepressants
If you have heard horror stories about antidepressant withdrawal, those stories most often involve drugs like venlafaxine, duloxetine, or paroxetine. A published review of antidepressant withdrawal data found that serotonin-norepinephrine reuptake inhibitors (the class that includes venlafaxine and duloxetine) and the SSRI paroxetine are associated with higher withdrawal risks than other antidepressants.1PubMed Central. Estimating Risk of Antidepressant Withdrawal from a Review of Published Data Trazodone was not flagged as a high-risk drug in that analysis, though the same review noted that data for some antidepressants remain thin. The absence of alarming signals in the existing literature does not mean trazodone withdrawal never happens; it means it tends to be milder and shorter-lived than withdrawal from the more notorious drugs.
That relative mildness is worth keeping in perspective. Trazodone is one of the most commonly prescribed medications in the United States, and the vast majority of prescriptions are at low doses for insomnia rather than at the higher doses used for depression. Most withdrawal research focuses on antidepressant-dose use, so the experience of the large population taking 25 to 100 mg nightly for sleep is not well studied in formal trials. Clinicians generally report that low-dose sleep users have an easier time stopping, but some individuals at those doses still report meaningful discomfort when they quit abruptly.
Rebound Insomnia Versus Withdrawal
This distinction matters practically even if it feels academic when you are lying awake at 3 a.m. Rebound insomnia is a temporary worsening of sleep that results from removing a sedating drug. It typically shows up the first night or two after stopping and resolves within one to two weeks. It does not necessarily mean you are dependent on trazodone or that your original insomnia has returned; it means your brain’s sleep-wake circuitry is recalibrating after losing a chemical push toward drowsiness.
True withdrawal, by contrast, involves a broader constellation of symptoms beyond just poor sleep. If you are also experiencing significant anxiety, gastrointestinal disturbance, mood instability, or physical discomfort, that points toward a discontinuation syndrome rather than simple rebound. The management is the same in both cases: slow down the taper, stabilize at a comfortable dose, and try again with smaller steps. But understanding the difference can help you avoid the common mistake of concluding that your underlying condition has relapsed, which might lead you to restart the medication at full dose when a slower taper would have been enough.
Relapse of the original condition, whether depression or chronic insomnia, is also a real possibility after stopping any treatment. If symptoms emerge weeks or months after a completed taper and do not fit the pattern of withdrawal (which typically starts within days), that is more likely to be a return of the original problem than a lingering discontinuation effect. Distinguishing the two sometimes requires patience, careful observation, and input from whoever prescribed the medication.
When Withdrawal Lasts Months or Longer
Most trazodone withdrawal resolves within a few weeks. But a subset of people who stop antidepressants of any class report symptoms that persist far longer, a phenomenon sometimes called protracted withdrawal syndrome. An analysis of consumer narratives from a large online support community examined 69 cases of protracted antidepressant withdrawal and found that symptoms lasted anywhere from five months to nearly fourteen years, with a median duration of about two years.2PubMed Central. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum Roughly four in five people in that sample reported mood-related symptoms like anxiety, depression, agitation, and emerging suicidal thoughts, while three in four reported physical symptoms including headaches, fatigue, dizziness, brain zaps, and muscle aches.3PubMed Central. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum
A few caveats about that data are important. The sample was drawn from an internet forum specifically for people experiencing difficult withdrawal, so it captures the worst outcomes rather than typical ones. The study was not specific to trazodone; it covered antidepressants broadly. And the people reporting protracted symptoms had been on their antidepressant for a long time, with a median of roughly six and a half years before stopping.4PubMed Central. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum Still, the existence of protracted withdrawal is increasingly acknowledged in clinical literature, and it underscores why a cautious taper matters, especially for long-term users.
How to Taper Safely
There is no single taper schedule that works for everyone. General clinical practice suggests reducing the dose by about 25 percent every one to two weeks, but this is a rough guideline rather than an evidence-based protocol, and many people find they need slower reductions, especially in the final stretch. The last portion of a taper, going from a small dose to zero, is often the hardest step, because the proportional drop is largest relative to what your body has adjusted to.
For people on standard tablets, the most common approach is to cut doses in steps: from 150 mg to 100 mg, then to 50 mg, then to 25 mg, and then off. If symptoms flare at any step, the standard advice is to hold at the current dose until things stabilize and then try a smaller reduction. Some clinicians recommend even gentler reductions, like going from 25 mg to 12.5 mg (half a tablet) before stopping entirely.
For people who need finer dose control than commercial tablets allow, compounded liquid formulations are sometimes used. A liquid preparation lets you reduce by tiny increments on a daily or weekly basis, which can be helpful for individuals who have struggled with even modest step-downs. The practical barrier is access: not all pharmacies compound trazodone in liquid form, and insurance coverage can be inconsistent. Some people split tablets with a pill cutter for intermediate doses, which works reasonably well for unscored tablets as long as the split portions are roughly even.
One thing to keep in mind is that trazodone is not considered physiologically dangerous to stop abruptly in the way that benzodiazepines or alcohol can be. Stopping trazodone cold turkey can be unpleasant, but it does not carry a risk of seizures or other medically dangerous complications in otherwise healthy people. The purpose of tapering is comfort and symptom management, not safety in the acute medical sense. That said, the psychological toll of severe discontinuation symptoms, especially anxiety and emerging depressive episodes, should not be dismissed just because the process is not medically dangerous.
What to Watch For During a Taper
Knowing what is normal during a taper can keep you from panicking or making unnecessary changes. Mild sleep disruption after each dose reduction is expected and usually resolves within a week. Brief upticks in anxiety or irritability are also common in the first few days after a step-down. These are signs that your body noticed the change, not signs that the taper is failing.
Symptoms that warrant slowing down or pausing include persistent insomnia that does not improve after a week, significant worsening of mood that feels qualitatively different from your baseline, new physical symptoms like dizziness or nausea that interfere with daily functioning, or a general sense that you cannot stabilize. If you are tapering under medical supervision, this is the kind of feedback your prescriber needs to adjust the schedule.
One common pitfall is confusing withdrawal with relapse, particularly for people who were taking trazodone for depression. Withdrawal symptoms tend to appear within the first few days of a dose reduction and often have a physical component (nausea, headache, dizziness) that is not typical of a depressive relapse. A depressive relapse, by contrast, tends to develop more gradually over weeks and looks like the original illness returning. If you are uncertain, holding at your current dose for a few weeks is a reasonable way to test: withdrawal symptoms will usually improve with time at a stable dose, while a genuine relapse will not.
Trazodone as a Tool for Managing Other Withdrawal Syndromes
An interesting wrinkle in the trazodone story is that the same drug people sometimes struggle to stop is also used to help manage withdrawal from other substances. Trazodone’s sedating and anxiolytic properties make it useful in psychiatric inpatient settings where patients are going through acute withdrawal from alcohol, benzodiazepines, or other drugs. A naturalistic study comparing intravenous and oral trazodone in this context found that the intravenous formulation showed better short-term results in managing withdrawal symptoms among hospitalized psychiatric patients.5Clinical Neuropsychopharmacology and Addiction. Intravenous vs. Oral Trazodone in the Management of Withdrawal Symptoms in Psychiatric Inpatients: A Naturalistic Study
This dual identity, a medication that can cause its own withdrawal yet helps treat withdrawal from other drugs, is not unusual in psychopharmacology. Many medications used in addiction and withdrawal medicine have discontinuation effects of their own. The clinical calculus is straightforward: the benefit of using trazodone to safely manage a potentially dangerous withdrawal from another substance outweighs the manageable discomfort of eventually tapering off trazodone itself.
Factors That Raise Your Personal Risk
Several factors make withdrawal more likely or more severe for a given individual. Duration of use is the strongest predictor. Someone who has taken trazodone nightly for five years has given their brain far more time to adapt to its presence than someone who used it for six weeks. Higher doses also correlate with more pronounced withdrawal, because the neurochemical shift upon stopping is larger.
Individual biology plays a role too. People who metabolize trazodone quickly (due to genetic variation in liver enzymes, particularly CYP3A4) may experience faster drops in blood levels and sharper withdrawal symptoms. Prior history of withdrawal from other medications, especially other serotonergic drugs, also seems to make people more sensitive. And there is a psychological component: if you are anxious about stopping, the vigilance itself can amplify the perception of symptoms, making it harder to distinguish true withdrawal from anxiety about withdrawal.
Age matters in a less obvious way. Older adults are more likely to have been on trazodone for extended periods, often for chronic insomnia, and they metabolize drugs more slowly on average. The slower metabolism can be a double-edged sword: it may buffer against sharp drops in drug levels, but it also means the taper process takes longer and requires more patience. Older adults are also more likely to be on multiple medications, and some drug interactions can affect how quickly trazodone clears the body, which in turn affects how a taper should be paced.
When Your Doctor Says It Is “Not Addictive”
You may have been told that trazodone is not addictive, and in the strict pharmacological sense, that is accurate. Trazodone does not produce the craving, compulsive use, and escalating dose patterns that define addiction. It is not a controlled substance and has negligible abuse potential. But “not addictive” is not the same as “easy to stop.” Physical dependence, meaning the body adapts to the drug’s presence and reacts when it is removed, can develop with any medication taken regularly for long enough, including trazodone. The language gap between how clinicians use “addiction” and how patients hear it creates a lot of frustration when someone who was reassured that their sleep medication is harmless finds themselves dealing with weeks of insomnia and anxiety after stopping.
This is not a reason to avoid trazodone or to be afraid of it. For many people it is an effective and well-tolerated option for insomnia or depression. But it is a reason to plan the exit strategy before or soon after you start, especially if you have a history of difficulty stopping other medications. Knowing that a slow taper will probably be needed is not alarming information; it is practical information that prevents the unpleasant surprise of discovering it the hard way.